<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362901">
  <stage>Registered</stage>
  <submitdate>14/08/2012</submitdate>
  <approvaldate>15/08/2012</approvaldate>
  <actrnumber>ACTRN12612000864820</actrnumber>
  <trial_identification>
    <studytitle>Investigation of whether metformin can be used safely and effectively in patients with type 2 diabetes on peritoneal dialysis</studytitle>
    <scientifictitle>A short term study of safety and glycaemic outcomes in  peritoneal dialysis patients with type 2 diabetes treated with metformin</scientifictitle>
    <utrn>U1111-1133-4789</utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <healthcondition>Chronic kidney Disease- on peritoneal dialysis</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Metformin 250 mg orally (half a 500mg tablet once a day) for 4 weeks of active treatment while continuing participants' existing peritoneal dialysis treatment. Peritoneal dialysis is not standardised</interventions>
    <comparator>Own control- participants will have baseline glycaemic measures (via HbA1c and via the continuous blood glucose monitoring and via measures of insulin sensitivity) prior to treatment and be used as their own comparator for repeat testing after 4 weeks of metformin therapy.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetics of metformin in the setting of peritoneal dialysis</outcome>
      <timepoint>Metformin plasma concentrations matched with metformin peritoneal dialysis concentrations hourly 1-6 hours post first dose and post last dose at steady state (4 weeks later). In between trough metformin concentrations (plasma and peritoneal dialysis fluid and urine) weekly.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety of metformin in peritoneal dialysis</outcome>
      <timepoint>Baseline and weekly lactate, bicarbonate and pH concentrations.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To describe the pharmacodynamic effects of metformin in patients on peritoneal dialysis treated with metformin- evaluating insulin sensitivity pre and post treatment and blood glucose concentrations</outcome>
      <timepoint>Continous blood glucose monitor worn for 72 hours in the week prior and the final week of treatment.
Own blood glucose concentrations 3-4 times a day.
Fasting glucose and insulin for Homeostasis Model Assessment (HOMA2) of insulin sensitivity pre treatment and final week of treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(1)&gt;18 years old
(2)Type 2 DM
(3)Peritoneal Dialysis treatment of chronic kidney disease
(4)Patients in whom metformin would be used if they had normal renal function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(1)Any patient in whom metofrmin would not be used in the setting of normal renal function- moderate-severe heart failure, liver failure, alcohol abuse, major psychaitric disorder, acutely unwell or otherwise medically unstable.
(2)Unability or unwilling to measure own blood glucose concentrations via glucometer.
(3)Inability to provide written informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/09/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>6</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Tilenka Thynne</primarysponsorname>
    <primarysponsoraddress>Department Clinical Pharmacology ,Flinders Medical Centre
Flinders Dr,
Bedford Park
SA 5042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Department Clinical Pharmacology ,Flinders Medical Centre</fundingname>
      <fundingaddress>Flinders Dr,
Bedford Park
SA 5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Matthew Doogue</sponsorname>
      <sponsoraddress>Flinders Dr,
Bedford Park
SA 5042</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a study aiming to evaluate whether metformin, an antidiabetic medication, can be used safety and effectively in patients with type 2 diabetes who are receiving peritoneal dialysis for their end stage kidney disease. The study runs over 4 weeks of active treatment, 250mg of metformin daily orally.
We hypothesise that metformin can be safely used in patients with type 2 diabetes with end stage renal failure if dosed based on predicted drug clearance.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Adelaide Clinical Human Research Ethics Committee (SAC HREC)</ethicname>
      <ethicaddress>Flinders Dr,
Bedford Park
SA 5042</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>16/08/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Matthew Doogue</name>
      <address>Department of Clinical Pharmacology
Flinders Dr,
Bedford Park
SA 5042</address>
      <phone>+61 8 82045511</phone>
      <fax />
      <email>matt.doogue@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Tilenka Thynne</name>
      <address>Department of Clinical Pharmacology
Flinders Dr,
Bedford Park
SA 5042</address>
      <phone>+61 8 82045511</phone>
      <fax />
      <email>tilenka.thynne@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Tilenka Thynne</name>
      <address>Department of Clinical Pharmacology
Flinders Dr,
Bedford Park
SA 5042</address>
      <phone>+61 8 82045511</phone>
      <fax />
      <email>tilenka.thynne@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>